• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mediwound Ltd Ord Sh (NQ: MDWD )

    17.10 +0.06 (+0.35%)
    Streaming Delayed Price Updated: 11:01 AM EDT, Sep 4, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mediwound Ltd Ord Sh

    < Previous 1 2 3 4 5 Next >
    MediWound to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces U.S. Food and Drug Administration Approval of NexoBrid® for the Treatment of Pediatric Patients with Severe Thermal Burns
    Approval Helps Solidify NexoBrid’s Position in the U.S. as a Safe and Effective Non-Surgical Burn Treatment for All Ages 
    From MediWound Ltd.
    Via GlobeNewswire
    MDWD Stock Earnings: MediWound Misses EPS, Beats Revenue for Q2 2024
    MDWD stock results show that MediWound missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    MediWound Reports Second Quarter 2024 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    Preview: MediWound's Earnings
    Via Benzinga
    Recap: MediWound Q3 Earnings
    Via Benzinga
    MediWound Announces Positive Results from the U.S. NexoBrid® Expanded Access Protocol (NEXT)
    NEXT Confirms NexoBrid's Proven Safety and Efficacy in Eschar Removal, Significantly Reducing Surgical Procedures for Burn Patients 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Report Second Quarter 2024 Financial Results
    Conference Call and Webcast Scheduled for Wednesday, August 14th at 8:30 am Eastern Time 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Publication of the EscharEx® Phase II ChronEx Study Results for Venous Leg Ulcers
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces €16.25 Million Funding from the European Innovation Council Accelerator Program
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces $25 Million Strategic Private Placement Financing
    Mölnlycke Health Care, a global leader in innovative wound care solutions, leads the PIPE with a $15 million investment 
    From MediWound Ltd.
    Via GlobeNewswire
    Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family 
    Via Benzinga
    US Stocks Mixed; Jobs Figures Top Estimates For June
    Via Benzinga
    Why Sharps Technology Shares Are Trading Higher By Around 32%; Here Are 20 Stocks Moving Premarket
    Shares of Sharps Technology, Inc. (NASDAQ:STSS) rose sharply in today's pre-market trading after the company announced it received two purchase orders for a total of approximately one million... 
    Via Benzinga
    MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q1 2024
    MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    MediWound Reports First Quarter 2024 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Report First Quarter 2024 Financial Results
    Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Present New Data from EscharEx® Phase II Studies at Three Leading Wound Care Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Ltd. (NASDAQ: MDWD) Sets New 52-Week High in Wednesday Session
    Via Investor Brand Network
    MDWD Stock Earnings: MediWound Beats EPS, Beats Revenue for Q4 2023
    MDWD stock results show that MediWound beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    MediWound Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
    From MediWound Ltd.
    Via GlobeNewswire
    Earnings Scheduled For March 21, 2024
    Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
    Via Benzinga
    MediWound to Report Fourth Quarter and Full Year 2023 Financial Results
    Conference Call and Webcast Scheduled for Thursday, March 21st at 8:30 am Eastern Time 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
    Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients... 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound to Participate in Two Upcoming Investor Conferences
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces that FDA has Accepted for Review the Supplement to the NexoBrid BLA to Include Pediatric Patients with Severe Thermal Burns
    From MediWound Ltd.
    Via GlobeNewswire
    Innovative Burn Care: MediWound Bags Additional DoD Grant For NexoBrid Development
    Biopharmaceutical company MediWound Ltd (NASDAQ: MDWD) reported that the U.S. 
    Via Benzinga
    MediWound Secures Additional U.S. Department of Defense Funding to Advance NexoBrid® Development for the U.S. Army
    Awarded additional $6.7 million to advance NexoBrid as a non-surgical field care solution; R&D project budget increased to $14.4 million 
    From MediWound Ltd.
    Via GlobeNewswire
    MediWound Announces Peer-Reviewed Publication of EscharEx® Mechanism of Action Study Assessing Its Effects on Biofilm and Microbial Loads
    Results show EscharEx to be safe and effective, and suggest it can go beyond traditional expectations for enzymatic debridement 
    From MediWound Ltd.
    Via GlobeNewswire
    Earnings Scheduled For November 21, 2023
    Companies Reporting Before The Bell • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.11 per share on revenue of $149.42 million. 
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.